<DOC>
	<DOCNO>NCT02754115</DOCNO>
	<brief_summary>Peritoneal carcinomatosis common event natural history colorectal digestive tract cancer . Cytoreductive surgery ( CRS ) hyperthermic intraperitoneal chemotherapy ( HIPEC ) provide promising therapeutic option highly select patient peritoneal carcinomatosis arise different malignancy colorectal cancer , gastric cancer , ovarian cancer , peritoneal mesothelioma improvement patient survival quality life . CRS , i.e. , removal visible metastatic abdominal pelvic disease peritonectomy along HIPEC ( 90 min temperature 42ยบ C ) and/or early postoperative intraperitoneal chemotherapy ( EPIC ) order eradicate microscopic metastasis . CRS HIPEC long complex procedure significant blood fluid loss debulking , hemodynamic , hematological , metabolic alteration HIPEC phase , even early postoperative period , resultant significant morbidity mortality . Despite report patient American Society Anesthesiologist class I II , without significant comorbidities systemic disorder ; morbidity mortality range 12 65 % procedure , well coordinate team anesthesiologist , surgeon intensivist ancillary service result good outcome . This study see challenge face team regard pathophysiological alteration CRS HIPEC perioperative period .</brief_summary>
	<brief_title>An Audit Cytoreductive Surgery Hyperthermic Intraperitoneal Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Peritoneal Diseases</mesh_term>
	<criteria>1 . Age 18 70 year 2 . ASA Class I III 3 . Colorectal gynecological oncology case post CRS HIPC . 1 . Age less 18 70 year 2 . ASA Class IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>